Table 5. Chronic oral treatment with minocycline prevents increases in pro-inflammatory cytokines in the PVN and PFC at 8 weeks post MI.
| Sham (n = 11) |
MI + Vehicle (n = 12) |
MI + Minocycline (n = 8) |
|
|---|---|---|---|
|
(pg/mg) PVN |
|||
| IL-1α | 15±1 | 29±5 ** | 11±2 |
| IL-1β | 33±4 | 39±2 | 32±4 |
| IL-2 | 58±6 | 86±9 ** | 55±8 |
| IL-6 | 244±43 | 256±16 | 215±8 |
| TNF-α | 127±14 | 135±6 | 116±4 |
| IL-10 | 233±21 | 267±25 | 154±3*† |
| PFC | |||
| IL-1α | 13±1 | 16±1 ** | 10±1 |
| IL-1β | 49±4 | 53±2 | 53±2 |
| IL-2 | 41±2 | 46±3 | 42±2 |
| IL-6 | 310±24 | 389±31** | 268±25 |
| TNF-α | 197±13 | 235±11* | 204±2 |
| IL-10 | 193±12 | 233±14** | 167±8 |
Values are means ± SE
One-way ANOVA for PVN, IL-α: F = 7.1, p = 0.004; for IL-2, F = 4.9, p = 0.02; and
for IL-10, F = 6.8, p = 0.004
One-way ANOVA for PFC, IL-α: F = 8.7, p = 0.002; for IL-6, F = 4.7, p = 0.02;
for TNF-α: F = 3.8, p = 0.04; and for IL-10, F = 6.2, p = 0.006
* p<0.05 vs. Sham,
** p <0.05 vs. Sham or MI+Mino,
† p <0.05 vs. MI+Veh.